Tracking sector rotations has been a tiring exercise so far this year with sentiment changing fast about growth, central banks’ next stop, the pandemic capitulating…
Unlike most Big Pharmas – which had a tough time post the COVID-19 outbreak, AstraZeneca witnessed a phenomenal run, with its share price hitting an…
Getinge reported strong Q1 21 numbers, beating estimates. Sales were up 12.6% on an organic basis, driven by the strength in acute care (+12.9%) and…
Boskalis is a leading dredging company part of a de facto oligopoly as the four European players, namely Boskalis, Van Oord, De Nul and DEME,…
Concerns surrounding the EU’s COVID-19 vaccination campaign refuse to die down. With AstraZeneca now reporting a safety scare – after already acknowledging supply constraints, export…
Since our last Teaser in November 2019, it has been a roller-coaster ride for Sanofi. While an impressive mid-term growth strategy and robust Q4-19 results…
We looked at stocks that stood in the best decile of performers both last week to 08/01/2021 inclusive and last month. This could be called…
Tesla makes the news with its all-time high and rising, up to its inclusion in the S&P500 by mid-December. But, over the last month, its…
It immediately appeared that the BioNTech(licensed by Pfizer) vaccine news of last week would trigger a logistics challenge of gargantuan proportions. As a reminder, usual…
BCP has been one the worst performers among our banks’ universe year-to-date. At -60%, the stock has managed to double the sector’s correction. This could…